We are live on ! Find out more
GALT icon

Galectin Therapeutics
GALT

52 hedge funds and large institutions have $9.77M invested in Galectin Therapeutics in 2017 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 13 increasing their positions, 7 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

233% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 3

86% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 7

29% more call options, than puts

Call options by funds: $866K | Put options by funds: $672K

17% more capital invested

Capital invested by funds: $8.34M → $9.77M (+$1.43M)

16% more funds holding

Funds holding: 45 → 52 (+7)

0.83% more ownership

Funds ownership: 10.65% → 11.48% (+0.83%)

Holders
52
Holders Change
+7
Holders Change %
+15.56%
% of All Funds
1.3%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
13
Reduced
7
Closed
3
Calls
$866K
Puts
$672K
Net Calls
+$194K
Net Calls Change
-$318K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$357K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$230K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$227K
4
BlackRock
BlackRock
New York
+$196K
5
ARTA
A.R.T. Advisors
New York
+$122K

Top Sellers

Rank Fund Capital Flow
1
Charles Schwab
Charles Schwab
California
-$349K
2
DADC
D.A. Davidson & Co
Montana
-$165K
3
Citadel Advisors
Citadel Advisors
Florida
-$57K
4
TSS
Two Sigma Securities
New York
-$35K
5
WAM
Wolverine Asset Management
Illinois
-$15K
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$42K -$711 -267 -2%
RG
27
Rathbones Group
United Kingdom
$40K – – –
LWAC
28
Laurel Wealth Advisors (California)
California
$39K +$2.66K +1,000 +7%
CAN
29
Cetera Advisor Networks
California
$38K +$41.9K +15,721 New
Citadel Advisors
30
Citadel Advisors
Florida
$33K -$57K -21,409 -62%
Wells Fargo
31
Wells Fargo
California
$30K – – –
GC
32
Guggenheim Capital
Illinois
$29K – – –
State Street
33
State Street
Massachusetts
$28K – – –
Millennium Management
34
Millennium Management
New York
$27K +$29.3K +11,000 New
DAS
35
Dynamic Advisor Solutions
Arizona
$25K +$26.6K +10,000 New
AIM
36
Acrospire Investment Management
Illinois
$16K +$17.5K +6,575 New
IA
37
IFP Advisors
Florida
$15K – – –
Bank of America
38
Bank of America
North Carolina
$14K -$208 -78 -1%
SEI Investments
39
SEI Investments
Pennsylvania
$9K +$10.1K +3,800 New
UBS Group
40
UBS Group
Switzerland
$6K -$3.44K -1,292 -35%
First Manhattan
41
First Manhattan
New York
$4K – – –
CG
42
Cutler Group
California
$4K +$2.4K +900 +82%
Creative Planning
43
Creative Planning
Kansas
$3K +$2.66K +1,000 +667%
NFG
44
Next Financial Group
Texas
$2K – – –
PRS
45
Pinkerton Retirement Specialists
Idaho
$2K – – –
RAM
46
Riggs Asset Management
Pennsylvania
$2K – – –
TWA
47
TCI Wealth Advisors
Arizona
$1K – – –
IWM
48
IHT Wealth Management
Illinois
$23 – – –
TSS
49
Two Sigma Securities
New York
– -$35K -15,243 Closed
WAM
50
Wolverine Asset Management
Illinois
– -$15K -6,715 Closed
1
2
3

GALT Hedge Fund Activity: Q2 2017 in Review

52 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q2 2017, worth a combined $9.77M — up 17% from $8.34M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new GALT positions and 3 closed out — a net gain of 7 holders — while 13 added to existing stakes and 7 trimmed.

The largest buyer was Vanguard Group, adding an estimated $357K. The largest seller was Charles Schwab, cutting an estimated $349K.

  • 52 institutional investors held Galectin Therapeutics (GALT) as of Q2 2017, up from 45 in Q1 2017.
  • Funds reported $9.77M of Galectin Therapeutics stock for Q2 2017, up 17% quarter-over-quarter.
  • 10 funds opened new Galectin Therapeutics positions in Q2 2017 and 3 closed out, a net change of +7 holders.
  • The largest Galectin Therapeutics buyer in Q2 2017 was Vanguard Group, an estimated $357K added.
  • The largest Galectin Therapeutics seller in Q2 2017 was Charles Schwab, an estimated $349K sold.

Based on aggregated 13F filings for Q2 2017.